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Initial observations on the 
implementation of a clinical 
pharmacy service in a rural 
hospital in Austria
Clinical pharmacy services (CPS) are rare in Austria, with only 15.8% of all hospitals having  
a dedicated pharmacy department, and even fewer offering CPS. Many countries have demonstrated 
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ABSTRACT
AIM To determine which types of clinical pharmacy 
interventions are needed at a small rural 360-bed 
hospital in Austria, and to assess the physicians’ 
acceptance rate of the pharmacists’ suggestions.
METHODS  Data on interventions made by one 
clinical pharmacist were collected over a six-month 
period and rated on a six-point clinical significance 
scale. A subset of 30 interventions was rated for 
clinical significance by four independent consultants 
to determine inter-rater reliability. 
RESULTS
During the six-month period, 255 clinical pharmacy 
interventions were made. In a subset of 159 patients, 
95 met the criteria for medication review which 
resulted in 140 interventions being made. Clinical 
pharmacy input was needed by 59.8% (98/159) of 
patients, requiring on average 1.5 interventions 
per patient. Acceptance rate was 59.5% (153/255), 
a change was considered by the physician involved, 
but not immediately followed through with in 40.0% 
(102/255). Average score for clinical significance 
intervention rating was 2.18. Inter-rater reliability 
(IRR) agreement was ‘good’ between the four 
consultants, and the four consultants with the 
pharmacist, respectively.
CONCLUSION Clinical pharmacy services (CPS) are 
needed and well accepted in Austrian hospitals. 
The clinical pharmacist is a missing member of 
the multidisciplinary ward team, a key player in 
reducing adverse drug reactions and improving 
patient safety, enabling treatment to become more 
holistic and patient-centred.
Clinical pharmacy services (CPS) have evolved 
greatly in recent years. In some countries they 
are normal practice, whereas in many, they do not 
exist. In Austria, only 15.8%1 of all hospitals have  
a pharmacy department, with only a few regularly 
providing CPS. In terms of numbers there is one 
hospital pharmacist per 300 patients.2 Stereotypical 
and traditional role models for both medical and 
pharmacy staff make it difficult to widen the scope 
of CPS. Medical staff are beginning to recognise the 
worth of clinical pharmacists and although it is well 
recognised that clinical pharmacists have a positive 
impact on patient care and are positively received by 
both medical and nursing staff,3–9 more needs to be 
done in Austria in order to change stakeholders’ 
perspectives and to inform policy to deliver 
necessary legislative changes. Compared with the 
UK, pharmacists in Austria have not been deployed 
to a level commensurate with their education and 
training; for example, they cannot run clinics, or 
work in general practice surgeries to perform 
medication use reviews10 and further training to 
become an independent non-medical prescriber  
is still not available. This is in an environment in 
which both hospital doctors and GPs frequently 
complain about their immense workload,11  
a situation that could be alleviated by maximising 
the use of clinical pharmacists.
This study aims to demonstrate the need for CPS 
in hospitals across Austria, the acceptance rate of 
clinical pharmacy interventions by physicians and 
the impact on inpatient safety by having a clinical 
pharmacist supporting the ward team.
Methods 
Study site
This clinical service evaluation pilot study was 
undertaken at Tauernklinikum in Zell am See, 
Austria – a rural 360-bed clinic in the federal state of 
Salzburg. The clinical pharmacy interventions took 
place on the medical ward (72 beds), involving 
polypharmacy patients (with five or more prescribed 
medical preparations) who were chosen randomly 
by the clinical pharmacist. Randomisation on ward 
rounds took place, choosing the patient rooms first 
according to ward round groups and then 
performing medication reviews. The pharmacist 
requested a call as to when the ward round would 
start and would then come and join – so not all 
patients in the chosen rooms would be seen, 
depending on time available. Randomisation for 
remote (not attending the ward round physically) 
medical review was undertaken in a similar fashion. 
This would facilitate reaching the patients’ 
physicians. Instead of joining the ward round, the 
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TABLE 1
Types of clinical pharmacy interventions 
Type of clinical pharmacy intervention Examples
Non-compliance with guidelines or existing contraindications Patient with impaired liver function but no dose adjustment prescribed
Inadequate drug administration Prescription of half tablets where tablets were not splittable, thus 
creating the potential for dose dumping for modified-release tablets
Specific information and therapy discussion Patient with oral thrush and cortisone inhaler spray. Information to 
rinse mouth or brush teeth after use of inhaler or use inhaler before 
food
Prescribed medication dose was an overdose Maximum daily dose was prescribed twice as high as recommended 
for amlodipine (daily maximum dose is 10mg)
Medication was prescribed without an indication or lacking 
documentation
Muscle relaxants had been re-prescribed without checking for 
indication
Drug–drug interactions Concomitant prescription of fluconazole and digoxin
Documentation error in patient notes Wrong transfer of home medication to inpatient medication chart
Therapeutic drug monitoring (TDM) Patient with eGFR of 34 presenting with delirium; lithium and 
zuclopenthixol in current prescription – advise for TDM
Untreated indication (need for additional medication) Patient with HFpEF but no prescription for ACE inhibitor or  
AT1-receptor-antagonist
Occurrence of side effects Patient with oedema and headaches prescribed amlodipine
Prescribed medication dose was an underdose Pradaxa underdosed in patient with thrombosis under present DOAC 
therapy
Literature research Request of ward round doctor to check which of the patient’s 
medications could cause thrombocytopenia
pharmacist made suggestions on the phone or wrote 
notes in the patients’ electronic Kardex systems.
Data collection
The data were collected using convenience 
sampling, as part as the day to day job of the 
hospital’s clinical pharmacist. The document used to 
record clinical pharmacy interventions originated 
from a French publication,12 which was adapted for 
Austrian use by the “Arbeitsgemeinschaft 
österreichischer Krankenhausapotheker”.13 The 
document records the pharmacist’s initials, date of 
clinical pharmacy intervention, initials of the doctor 
who was involved, patient gender, patient age and 
details of the clinical pharmacy intervention  
(Table 1).
The number of patients reviewed for medication 
correctness was recorded on each day that clinical 
pharmacy interventions took place. Out of those 
interventions, the pharmacist recorded which 
patient records were relevant to review and the 
number of interventions made on that date. 
Non-polypharmacy patients were not included, and 
review did not take place when, on initial screening, 
no medication-related problems were found.
The clinical pharmacy interventions were rated 
by the pharmacist on a 6-point significance scale 
(Hatoum14). A number of the interventions were 
randomly chosen (those having a high variety of 
ATC-codes and different types of interventions) and 
additionally rated by four medical consultants. Each 
rating was carried out separately and without 
sharing the scores of their colleagues to minimise 
bias. The ratings were then evaluated, and a mean 
calculated for each coder, respectively.
A two-way model inter-rater reliability (IRR) 
analysis was performed for the four different 
consultant assessments using SPSS to determine 
intra-class correlation (ICC). This was then correlated 
with the pharmacist’s rating to decide whether it 
could be extrapolated to all 255 pharmacists’ 
intervention ratings. Common cutoff values based 
on ICC ratings between 0.75 and 1.0 were deemed 
excellent; good, between 0.60 and 0.74; fair for 
values between 0.40 and 0.59; and poor for values 
less than 0.40.15
Impact of COVID-19 on methods
Due to the impact of COVID-19 and the increasing 
daily workload in the hospital, the data that could 
be collected was reduced. Due to patient isolation, 
the pharmacist was restricted to pharmaceutical 
medication review remotely and not in person on 
the ward rounds. This resulted in less doctor–
pharmacist and nurse–pharmacist interaction.
Ethical considerations
The data from this small-scale service evaluation 
study was collected as a part of the researcher’s 
day-to-day job as a newly employed clinical 
pharmacist. It is only an early analysis of her work 
at Tauernklinikum, Zell am See and serves as a pilot 
study. For this reason, ethical approval was not 
required.
Results 
Total number of interventions
A total of 255 clinical pharmacy interventions 
Stereotypical and 
traditional role 
models for both 
medical and 
pharmacy staff 
make it difficult to 
widen the scope 
of CPS
FIGURE 1
Responses of ward round doctors concerning the 
pharmacist’s clinical interventions
were made from 21 September 2020 until 22 
February 2021. Of these, 104 were undertaken 
during remote pharmacy medication review and  
a further 151 on ward rounds. The average age of the 
patients needing an intervention was 73.57 (±1.64) 
years. Female patients accounted for 145 (56.9%; 
145/255) of 255 interventions, 110 (43.2%; 110/255) 
interventions were undertaken for male patients.
The total number of patients was not recorded for 
the complete set of 255 interventions. However, a 
subset of 159 patients was further reviewed and it 
was determined that 95 met the criteria 
(polypharmacy, age, high-risk drugs). There were 140 
interventions made in these 95 patients. It could 
therefore be hypothesised that 59.8% (98/159) of the 
patients in the medical ward need clinical pharmacy 
input, requiring on average 1.5 interventions per 
patient.
Of all interventions undertaken, prompt 
acceptance rate by the physicians involved was 
59.6% (152/255). In 39.2% (100/255) of all cases a 
change was considered by the physician, but in the 
course of this pilot study it was not followed up 
further by the pharmacist as to whether the 
intervention led to a change subsequently (Figure 1) 
due to a lack of resources and time. None of the 
suggested clinical pharmacy interventions were 
declined. In some cases, a discussion between the 
pharmacist and the ward round physician led to a 
different change than the pharmacist had initially 
suggested, which was then classified as 
“intervention considered by physician”.
Figure 2 shows which types of clinical 
pharmaceutical interventions were made. One 
intervention could be rated as multiple types of 
interventions.
Significance of interventions
The overall average score for all 255 clinical 
pharmaceutical interventions taken was 2.18. Figure 
3 shows the distribution of these scores. Of all 
interventions, 94.9% (242/255) were rated “2”; that is, 
a significant pharmaceutical intervention, or higher. 
This indicates clinical pharmacy interventions in 
Tauernklinikum in Zell am See enhance patient 
welfare and – according to the Hatoum scale14 – 
could potentially eliminate organ failure caused by 
medication errors or potentially fatal outcomes.
Interventions were rated for significance by the 
clinical pharmacist. To show IRR, 30 interventions 
were chosen randomly for rating by four consultant 
doctors on the medical ward as illustrated in Figure 
4. The clinical pharmacist rated the 30 interventions 
with a mean of 2.43. Three of the consultants rated 
with a mean of 2.73, whilst one had a lower rating 
with a mean of 2.03.
ICC average measurement of the four consultant 
coders was 0.725 with a lower confidence interval of 
0.519 and an upper confidence interval of 0.856. For 
absolute agreement the average measurement was 
0.672, with a lower confidence interval of 0.429 and 
an upper confidence interval of 0.828. The calculated 
ICC values both indicate “good” agreement between 
the four coders.15 Single measures were low, namely 
0.397 and 0.339 for consistency and absolute 
agreement, respectively.
When those numbers were correlated with the 
pharmacist’s scores, ICC for consistency was 0.660 
and 0.622 for absolute agreement, thus both can be 
considered as “good”.15
Figure 5 depicts the potential for cost reduction 
associated with the recommended pharmaceutical 
changes, namely with medication being stopped 
(84/255; 32.8%), a dose reduction (73/255; 28.9%) and 
the remaining 98/255 (38.3%) of interventions not 
yielding cost reductions.
Discussion 
Total number of pharmaceutical interventions
Research across Europe and the UK has shown that 
acceptance rates for clinical pharmacy interventions 
vary widely.16–21 Around 59.8% (98/159) of the sample 
of patients at Tauernklinikum Zell am See need 
clinical pharmaceutical interventions, thus it is 
apparent that more patients require medicines 
reconciliation and medicines review. Due to staffing 
constraints this is an issue in most Austrian 
hospitals. The clinical pharmacist is a missing link 
in the multidisciplinary ward team, for optimising 
medicine use, reducing adverse drug reactions and 
improving patient safety. The Chief Executive of the 
Society of Hospital Pharmacists of Australia stated in 
2018 that the maximum number of patients that 
one hospital pharmacist should have as a case load 
is 30.22 For a 360-bed hospital, as in this study, this 
equates to 12 full-time clinical pharmacists but, in 
fact, there are only 0.7 WTE.
Types of clinical pharmacy interventions
Non-compliance with guidelines was the main 
intervention type. The interventions related to 
expanding the scope of the individual patient 
treatment, unfamiliarity with guidelines and failing to 
dose modify in organ dysfunction. The second largest 
category was inappropriate drug administration.
The third category was DRP with missing specific 
information or lack of patient counselling. 
Consultants and registrars were open to, and 
accepting of, DRP discussions with the pharmacist. 
This underpins the statement work undertaken in  
Northern Ireland that concludes that the pharmacist 
has a complementary role in the ward 
multidisciplinary team.23
Of all interventions 
undertaken, 
prompt 
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Intervention led to change
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FIGURE 2
Types of clinical pharmaceutical interventions made on the medical ward at Tauernklinikum
FIGURE 3
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Significance ratings (Hatoum scale) for 30 interventions rated by four consultant doctors vs the 
clinical pharmacist
Clinical significance of pharmaceutical interventions
The suggested pharmaceutical intervention led  
to an immediate change in 59.6% (153/255). If the 
interventions, which were only recorded as 
“considered”, also led to a prompt change in 
prescribed medication, then an even higher number 
of pharmaceutical interventions would be directly 
accepted by the ward round physician. This strongly 
implies that clinical pharmacist input is an essential 
part of multidisciplinary ward teams, resulting in 
more holistic patient therapy. The physician can 
incorporate other professional opinions into their 
overall patient care plan, that is, not purely from the 
medical viewpoint with all the attendant benefits. 
The physician is then also able to include 
pharmaceutical thinking, psychological 
considerations, physiotherapist views etc, into their 
patient care. Numerous studies have shown that 
working in such an interdisciplinary manner can 
greatly improve patient care.4–9
Some rating differences could be explained by 
considering the different educational backgrounds 
of the four medical raters and the clinical 
pharmacist. The medical consultants rated 
interventions concerning QT-interval prolonging 
drugs and potential interactions thereof significantly 
higher (2 points) than the pharmacist. On 
subsequent individual discussions, they all stated 
that they have previously encountered problems in 
this field, leading to major adverse drug reactions, 
some of which had been fatal. They reported that 
cross-professional training for this particular subject 
would be desirable. They have experienced serious 
adverse events entailing this before and have 
become risk averse in this area.
The pharmacist, on the other hand, rated 
interventions where drug doses had not been 
adjusted according to kidney and liver function 
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Cost reduction potential of all 
clinical pharmaceutical 
interventions from September 2020 
to February 2021
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Austria is not very well developed in rural areas and 
still in its adaptation phase, these issues need to be 
addressed carefully and actions taken thoroughly 
and proficiently to allow for development of trust 
among the different professions.
Cost savings of pharmaceutical interventions
Clinical pharmacy work on the wards not only 
improves patient care but can also lead to cost 
reductions in medicines expenditure.24
Conclusions
Even though this study was only carried out on a 
very small scale, it has successfully demonstrated 
that there is great potential and a definite need for 
the development and increase of CPS in Austria. 
One of the main reasons why CPS are so 
underdeveloped in Austria is due to a very drug-
oriented- centred curriculum in the pharmacy 
degree with very little focus on patient-centric 
pharmacotherapy.25 Many clinical pharmacists in 
Austria have self-educated or obtained an additional 
clinical degree from overseas.2 Another reason CPS 
are underdeveloped in Austria is that there was no 
funding for such services via the insurance systems. 
However, this has now been remedied and CPS 
remunerated.26 This is revolutionary for CPS in 
Austria as revenue can be generated from the CPS 
that has been provided. This change now means that 
there is leverage regarding stakeholders to employ 
more clinical pharmacists and encourage medical 
staff to request CPS. Many countries have 
demonstrated the benefits of CPS in hospitals over 
the past 30 years or more. This research has done 
that, and proposed further work will demonstrate 
that CPS is also essential in Austria.
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significantly higher than the clinicians; physicians 
did not rate this as a major problem. Based on 
experience, they reported being able to push the 
limits of certain medications. Keeping the blood 
pressure low is the most important concern for 
patients needing dialysis, they stated.
Discrepancies between clinicians and pharmacists 
were due to different educational backgrounds and 
different levels of medical ward hospital experience. 
Rating these patient cases was instructive for both 
parties. Not only can the pharmacist learn from the 
physicians’ clinical experiences but also identify 
needs to support them further and enable more 
balanced medical decisions. As clinical pharmacy in 
 
Key points
• In Austria, CPS are 
rare, with only 15.8%  
of hospitals having  
a dedicated pharmacy 
department and even 
fewer offering CPS. 
• Many countries have 
demonstrated the 
benefits of CPS in 
hospitals over the past 
30 or more years.
• This study 
demonstrates the need 
for the development of 
CPS in Austria.
• Clinical pharmacists 
identified a range of 
clinical pharmacy 
interventions with 59.6% 
of suggested 
pharmaceutical 
interventions leading to 
an immediate change in 
patient care.
• A total of 95% of 
clinical interventions 
recommended by 
pharmacists were rated 
as ≥2 on the Hatoum 
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